此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

2026年6月2日 更新者:Robert Edwards、Kalinski, Pawel, MD, PhD

A Phase 2 Efficacy Trial of Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

This trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal infusion of a chemokine modulatory (CKM) regimen composed of a cocktail of IP rintatolimod and interferon-alpha (IFNα) for patients with advanced stage ovarian cancer (III-IV) in the primary neoadjuvant setting. It was previously determined the tolerable dose of IPC-CKM. This study will add intradermal (ID) autologous αDC1 vaccines (known to be nontoxic) to the tolerable IPC-CKM regimen and systemic Keytruda (pembrolizumab). To optimize the pattern of immunity, all patients will also receive oral celecoxib (COX2 inhibitor).

研究概览

详细说明

In addition to its typically late detection, the difficulty in treating OvCa results from its particular adeptness at avoiding immune elimination. Several vaccine trials targeting ovarian cancer have recently reported a lack of efficacy with vaccine only approaches. OvCa cells have been reported to display numerous defects in their MHC class I antigen-presenting capacity, involving loss of HLA alleles and loss of the molecules involved in the generation of antigenic peptides. In addition to these passive mechanisms of immune subversion, OvCa employs a series of active suppressive mechanisms, involving the suppression of endogenous immune cells and innate immune response pathways, and a particularly high ability to attract regulatory T cells (Tregs), mediated by elevated expression of CXCL12 and CCL22 2. It is suspected that massive chemotherapy-induced apoptosis may further promote this modulation by enhancing local immunity. These considerations suggest that effective immunotherapies of OvCa may need to involve countermeasures to both these modes (passive and active) of immune subversion. Since αDC1-induced CD8+ T cells express particularly high levels of the typical CTL-associated chemokine receptors (CXCR3 and CCR5), the therapeutic benefit of αDC1 vaccination is likely to be enhanced by the CKM therapies, able of selectively enhancing CXCL10 (and other CXCR3 ligands) as well as CCR5 ligands, such as CCL5/RANTES, in order to promote the entry of the vaccination-induced effector cells to tumor tissue.

研究类型

介入性

注册 (估计的)

28

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Lucia M Borrasso, RN, BSN
  • 电话号码:4126413304
  • 邮箱:borrlm@upmc.edu

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • UMPC Hillman Cancer Center
        • 首席研究员:
          • Robert Edwards, MD
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Patients must have advanced stage (III-IV) epithelial carcinoma or carcinosarcoma of ovarian, tubal or peritoneal origin.

    a. Histologic documentation of the original primary tumor is required via a pathology report.

  2. Patients must be eligible for cancer-related definitive therapy with neoadjuvant chemotherapy.
  3. Patients must be chemo-naive and receiving therapy in primary first-line neoadjuvant setting.
  4. Patients must have ECOG performance of 0-1.
  5. Patients must be reasonable candidate for interval debulking surgery as well as for IP platinum-based combination chemotherapy regimen, with no prior evidence of clinically significant intra-abdominal adhesions, persistent abdominal wall infections, renal disease or bowel obstruction.
  6. At least one lesion must be considered to be large enough for biopsy and resection to yield greater than 2 grams of tumor for tumor loading of αDC1's and immunoassays at the discretion of the treating investigator and/or surgeon.
  7. Patients must have measurable disease per iRECIST criteria.
  8. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception prior to study entry, during the course of the study, and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (e.g., condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods.
  9. Female subjects of childbearing potential must not be pregnant or breastfeeding at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met:

    a. Permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman > 45 years-of-age in the absence of other biological or physiological causes). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.

  10. Patients must be willing to undergo leukapheresis.
  11. Patients must be willing to adhere to protocol requirements.
  12. Patients must have adequate:

    1. Bone marrow function:

      • Absolute neutrophil count (ANC) greater than or equal to 1,500/μL
      • Platelets greater than or equal to 100,000/μL
      • Hemoglobin greater than or equal to 8.0 g/dL
    2. Renal function:

      - Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN)

    3. Hepatic function:

      • Bilirubin less than or equal to 1.5 x ULN
      • SGOT and alkaline phosphatase less than or equal to 2.5 x ULN
  13. Patients who have signed informed consent and authorization permitting release of personal health information.
  14. Patients must be ≥ 18 years of age.
  15. Patient must be able to swallow oral medication and have no absorption related medical concern as deemed by the investigator.

Exclusion Criteria:

  1. Patients with sarcoma.
  2. Patients who have an active autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis).
  3. Patients with a known allergy to cisplatin or taxane chemotherapy. Patients with carboplatin allergy may be included if they tolerate a test dose of IV cisplatin given in monitored floor conditions. Patients who are allergic to paclitaxel can be alternatively treated with abraxane.
  4. Patients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids.

    a. Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.

  5. Patients with a recognized immunodeficiency disease including cellular immunodeficiencies, hypogammaglobulinemia or dysgammaglobulinemia; patients who have acquired, hereditary, or congenital immunodeficiencies.
  6. Patients with uncontrolled diseases other than cancer will be excluded.
  7. Patients who have contraindications to the use of NSAID's like chronic renal failure, coronary artery disease, or bleeding ulcers.
  8. Patients who have contraindications to the use of interferon α-2b (Bioferon), including hypersensitivity to interferon-α or any component of the product, autoimmune hepatitis, and decompensated liver disease.
  9. Patients with tumors of low malignant potential, except ovarian pseudomyxoma or with no peritoneal disease.
  10. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy.
  11. Patients with previous pelvic radiation therapy.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Safety Lead-in: Paclitaxel + Cisplatin + Bioferon + Rintatolimod + Pembrolizomab + Celecoxib

A chemotherapy for cancer patients that interferes structures that help move chromosomes during cell division, thus stabilizing these structures to prevents cancer cells from dividing and ultimately causing them to die.

Dose: 175 mg/m^2 IV on D1 each cycle during neoadjuvant and adjuvant periods.

其他名称:
  • 紫杉醇
  • 紫杉烷

An alkylating agent that contains platinum, which binds to DNA in cancer cells, causing cross-links that prevent DNA replication and repair, leading to cell death, particularly in rapidly dividing cancer cells.

Dose: 75 mg/m^2 IP / 1 hour on D1 of each cycle during neoadjuvant and adjuvant treatment periods.

其他名称:
  • Platinol®

Inhibits replication of a wide range of RNA and DNA viruses and exerts antiproliferative effects on malignant cells. It suppresses antibody formation through an effect on B-lymphocytes and inhibits onset of delayed hypersensitivity.

Dose:6 milli on units/100 mL IP over 30-60 minutes on D2 of each cycle during neoadjuvant and adjuvant treatment. D1 during maintenance treatment periods.

其他名称:
  • (Interferon Alfa)-2a

A synthetic double-stranded RNA that selectively activates Toll-like Receptor 3 (TLR3), triggering antiviral and immunomodulatory responses, priming the immune system without causing excessive inflammation.

Dose: 200 mg IP over 1-2 hours on D2 of each cycle during the neoadjuvant and adjuvant treatment periods. D1 during maintenance treatment periods

其他名称:
  • 安普利近®

Humanized monoclonal antibody and a PD-1 inhibitor used in cancer immunotherapy that differs from chemotherapy as it does not directly kill cancer cells but stimulates the immune system, particularly T-cells, to recognize and attack cancer cells more effectively.

Dose: 200 mg IV / 30 minutes on D2 of each cycle during neoadjuvant treatment period (none last neoadjuvant cycle), then optional on D2 for adjuvant treatment cycles, and on D1 of maintenance cycles

其他名称:
  • 可瑞达®
A COX-2 inhibitor in the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that specifically target the cyclooxygenase-2 (COX-2) enzyme, which plays a key role in inflammation Dose: 200mg/day, orally twice a day for days 1-5 and once a day for days 6-21 of neoadjuvant and adjuvant treatment cycles, and then twice a day on D1 and once a day for days 2-21 for maintenance cycles
其他名称:
  • 西乐宝®

A surgical procedure designed to remove the majority of cancerous tumors when complete removal may not be feasible, with the goal of reducing tumor burden, making follow-up treatments like chemotherapy or radiation more effective.

Surgery occurs in between the neoadjuvant and adjuvant treatment periods.

其他名称:
  • 细胞减灭术
实验性的:Paclitaxel + Cisplatin + Bioferon + Rintatolimod + DC1 Vaccine + Pembrolizomab + Celecoxib

A chemotherapy for cancer patients that interferes structures that help move chromosomes during cell division, thus stabilizing these structures to prevents cancer cells from dividing and ultimately causing them to die.

Dose: 175 mg/m^2 IV on D1 each cycle during neoadjuvant and adjuvant periods.

其他名称:
  • 紫杉醇
  • 紫杉烷

An alkylating agent that contains platinum, which binds to DNA in cancer cells, causing cross-links that prevent DNA replication and repair, leading to cell death, particularly in rapidly dividing cancer cells.

Dose: 75 mg/m^2 IP / 1 hour on D1 of each cycle during neoadjuvant and adjuvant treatment periods.

其他名称:
  • Platinol®

Inhibits replication of a wide range of RNA and DNA viruses and exerts antiproliferative effects on malignant cells. It suppresses antibody formation through an effect on B-lymphocytes and inhibits onset of delayed hypersensitivity.

Dose:6 milli on units/100 mL IP over 30-60 minutes on D2 of each cycle during neoadjuvant and adjuvant treatment. D1 during maintenance treatment periods.

其他名称:
  • (Interferon Alfa)-2a

A synthetic double-stranded RNA that selectively activates Toll-like Receptor 3 (TLR3), triggering antiviral and immunomodulatory responses, priming the immune system without causing excessive inflammation.

Dose: 200 mg IP over 1-2 hours on D2 of each cycle during the neoadjuvant and adjuvant treatment periods. D1 during maintenance treatment periods

其他名称:
  • 安普利近®

Humanized monoclonal antibody and a PD-1 inhibitor used in cancer immunotherapy that differs from chemotherapy as it does not directly kill cancer cells but stimulates the immune system, particularly T-cells, to recognize and attack cancer cells more effectively.

Dose: 200 mg IV / 30 minutes on D2 of each cycle during neoadjuvant treatment period (none last neoadjuvant cycle), then optional on D2 for adjuvant treatment cycles, and on D1 of maintenance cycles

其他名称:
  • 可瑞达®
A COX-2 inhibitor in the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that specifically target the cyclooxygenase-2 (COX-2) enzyme, which plays a key role in inflammation Dose: 200mg/day, orally twice a day for days 1-5 and once a day for days 6-21 of neoadjuvant and adjuvant treatment cycles, and then twice a day on D1 and once a day for days 2-21 for maintenance cycles
其他名称:
  • 西乐宝®

A surgical procedure designed to remove the majority of cancerous tumors when complete removal may not be feasible, with the goal of reducing tumor burden, making follow-up treatments like chemotherapy or radiation more effective.

Surgery occurs in between the neoadjuvant and adjuvant treatment periods.

其他名称:
  • 细胞减灭术

Autologous tumor-loaded alpha-DC1 vaccine is the new type of dendritic cell vaccine developed by our group, are the serum-free, clinically-applicable version of type-1 polarized DCs, combining a fully-mature phenotype and high expression of co-stimulatory molecules with an elevated, rather than exhausted, ability to produce IL-12p70.

Dose: 6 million dendritic cells (reduced or omitted if insufficient vaccine material), ID injection on rotating sides of lower extremities on D2 each cycle during the neoadjuvant (not C1) and adjuvant treatment periods. D1 of each cycle during maintenance period.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Dose Limiting Toxicities (DLT)
大体时间:Up to 2 months
Proportion of patients in the safety cohort (chemoimmunotherapy combined with the αDC1 vaccine) experiencing a dose-limiting toxicity (DLT). A DLT will be any adverse event that is at least possibly related to the study treatment and prevents surgery or delays surgery by more than 4 weeks, or that prevents the initiation of the next cycle of treatment on schedule due to toxicity in the prior cycle. The DLT period will be 2 cycles of treatment.
Up to 2 months
Complete Pathologic Response (pCR)
大体时间:Up to 5 years
Percentage of patients who show no detectable cancer (cells) in tissue samples after neoadjuvant treatment as assessed at the time of the interval debulking procedure. Per RECIST v1.1, Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in SLD compared to baseline, confirmed on a follow-up scan.
Up to 5 years

次要结果测量

结果测量
措施说明
大体时间
Treatment-related Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Up to 14 months
Number of patients who experience Adverse Events (AEs) and Serious Adverse Events (SAEs) least possibly related to treatment per CTCAE v 5.0.
Up to 14 months
12-month Progression-free Survival (PFS)
大体时间:At 12 months
Percentage of patients without disease progression per iRECIST at 12 months post treatment initiation. Per iRECIST, Progressive Disease (PD): At least a 20% increase in SLD from the nadir, with an absolute increase of ≥5 mm, or the appearance of any new lesion.
At 12 months
18-month Progression-free Survival (PFS)
大体时间:At 18 months
Percentage of patients without disease progression per iRECIST at 18 months post treatment initiation. Per iRECIST, Progressive Disease (PD): At least a 20% increase in SLD from the nadir, with an absolute increase of ≥5 mm, or the appearance of any new lesion.
At 18 months
Progression-free Survival (PFS)
大体时间:Up to 5 years
Median time from treatment initiation when 50% of patients have disease progression (per RECIST v1.1) or have died from any cause, whichever occurs first. Per RECIST v1.1, Progressive Disease (PD): At least a 20% increase in SLD from the nadir, with an absolute increase of ≥5 mm, or the appearance of any new lesion
Up to 5 years
Overall Survival (OS)
大体时间:Up to 7 years
Median time from treatment initiation when 50% of patients have died from any cause.
Up to 7 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Robert Edwards, MD、UPMC Magee Womens Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月1日

初级完成 (估计的)

2028年8月1日

研究完成 (估计的)

2029年8月1日

研究注册日期

首次提交

2026年6月2日

首先提交符合 QC 标准的

2026年6月2日

首次发布 (实际的)

2026年6月8日

研究记录更新

最后更新发布 (实际的)

2026年6月8日

上次提交的符合 QC 标准的更新

2026年6月2日

最后验证

2026年6月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅